Smithsonian scientists and colleagues working on Panama’s Barro Colorado Island discovered that small leaf samples from a single tree were home to more than…

Abundant supplies of natural gas will do little to reduce harmful U.S. emissions causing climate change, according to researchers at UC Irvine, Stanford…

Rice is a staple food across Asia, with both people and economies reliant on its successful harvest. One paper finds that low water input does not affect rice…

Anew U.S. Geological Survey study predicts where 50 bird species will breed, feed and live in the conterminous U.S. by 2075. While some types of birds, like…

Common free space optical communication systems use intensity modulation, which has the drawback of a low spectral efficiency. However, OMIMO is an improved concept for free space optical (FSO) communication. To enhance efficiency a coherent transmission is used with incoherent light sources.
At the transmitter a baseband signal is phase-shifted for precoding, spatial multiplexing or beam forming. After upconversion of the baseband signal to a bandpass signal a DC-offset is added. This signal drives a light source, e. g. an LED or a laser diode by direct modulation. The receiver works with a reverse scheme. For transmitting and receiving a plurality of light source and photo detector can be used in parallel, respectively, to establish an optical MIMO concept.

2STEP-CP is a method of communication between two (mobile) signal sources and a relay station with two antennas. In a first time slot, the two signal sources send a first signal, respectively, in a second time slot a second signal. Based on the respective first and second signals the relay station generates a first and a second network-coded signal. In a third time slot, the first network-coded signal is sent via the first antenna and the second network-coded signal is sent via the second antenna. In a fourth time slot, the two network-encoded signals are sent via the respective other antenna. Based on the signal the signal sources have sent in the first two time slots, both signal sources are able to decode the network coded signals from the relay station. The process is also adaptable to a higher number of signal sources and antennas per relay station.

The new design for energy storage systems is based on novel, prism-shaped housings for battery cells. Instead of conventionally contacting the cells via the cylinder covers the novel cell housing enables electrical connection of the individual cells by pressing together the side surfaces. The battery system is readily separable and improves safety, transport and maintenance. In addition, the invention enables flexible and rapid system design and cost-effective development processes.

The current technology provides the detection of DKK3 as a promising early stage marker for chronic kidney disease. DKK3 is elevated in the early morning urine and can be easily and cost-effectively determined by standard ELISA assay systems.

The antibody of this invention is a mouse monoclonal antibody directed against SUMO176-86 recognizing SUMO1 of human, mouse, chicken and X. laevis. It is suitable for western blot and immune precipitation as well as for large-scale enrichment of SUMOylated species by IP / peptide elution.

The invention reveals a method, based on metylation analysis of intragenic regions of the gene DGKA, for estimating the risk of developing radiation induced fibrosis and can therefore be used for therapy planning.

The invention discloses a device that enables bead purification and mixing of the sample without the need for moving the reaction plate from one deck position to the other and hence saving time and deck space.

The Mastomys mouse model is the only existing natural laboratory model to investigate PV pathogenesis and tumor development in the skin, ear, eye and tongue and could help to develop prophylactic or therapeutic approaches to prevent those lesions.

The invention shows that a combination of HDAC and ALK inhibitors for tumortherapy is surprisingly synergistic and can additionally overcome single substance drug resistance.

The present invention comprises the use of two serum/plasma markers for stage discrimination and prediction of survival as well as treatment response in breast cancer patients. Test statistics show that these markers outperform established ones like the number of circulating tumor cells (CTCs).

The invention discloses an improved version of the chorionallantic membrane, for accurate quantification of metastatic cells in different organs of the chicken embryo at a high sensitivity.

The invention identifies new mutations in the TERT promoter which qualify as diagnostic and prognostic marker.

The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.

Side effects limit the radio/chemotherapeutic doses used during cancer treatment. Rocaglamide A and derivatives show strong chemo- and radioprotective efficacy, are highly specific for normal cells and do not protect p53-deficient/mutated cancer cells.

Non-ribosomal peptides (NRPs) are secondary metabolites produced by microorganisms, e.g. bacteria and fungi. Unlike ribosomal protein bio-synthesis, non-ribosomal protein synthesis (NRPS) does not require mRNA. NRPs are a promising source of functional molecules such as antibiotics. The technology allows for the identification, high-throughput screening and easy purification of engineered NRPs by optical measures.

The technology allows for direct and indirect detection of cancer tissue. It deals with a pharmaceutical compound consisting of three subdomains: (A) for specific cell surface binding to neoplastic cells, (B) for binding radiometals via a chelator domain for e.g. PET, and (C) harboring a fluorescent dye moiety for optical detection. The combination of PET tracer and optical moiety enables the surgeon to localize the tumor preoperatively via PET/CT and intraoperatively through optical detection.